| Shari Landry Ot | |
|
1475 Folsom St Apt 3003, Boulder, CO 80302-6845 | |
| (203) 641-0492 | |
| Not Available |
| Full Name | Shari Landry Ot |
|---|---|
| Type | Facility |
| Speciality | Occupational Therapist - Pediatrics |
| Location | 1475 Folsom St Apt 3003, Boulder, Colorado |
| Accepts Medicare Assignments | Does not participate in Medicare Program. The facility may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1801447115 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225XP0200X | Occupational Therapist - Pediatrics | (* (Not Available)) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Shari Landry Ot 1475 Folsom St Apt 3003, Boulder, CO 80302-6845 Ph: (203) 641-0492 | Shari Landry Ot 1475 Folsom St Apt 3003, Boulder, CO 80302-6845 Ph: (203) 641-0492 |
News Archive
Pregnancy in adolescence has been linked with increased risks of mortality and life-threatening complications in young mothers and their newborn babies. New research suggests that biology alone does not explain the high incidence of these adverse outcomes.
Pro-Pharmaceuticals, Inc., the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company's novel, Galectin-targeting compounds.
Unigene Laboratories, Inc. announced today that Novartis has released information on the first of two studies on oral calcitonin for the treatment of osteoarthritis conducted by its license partner Nordic Bioscience. The recently completed Study 2301, which assesses the safety and efficacy of oral calcitonin in the treatment of knee osteoarthritis, had three co-primary endpoints.
A consumer watchdog group in the U.S., Public Citizen, has petitioned the U.S. Food and Drug Administration (FDA) to withdraw the prescription diet drug Xenical (orlistat) from the market; the group also want the FDA to refuse approval for the weight-loss pill to be made widely available over the counter.
Approximately 1 out of every 6 American men will be diagnosed with prostate cancer, and this year alone there are expected to be nearly a quarter of a million new cases diagnosed, making prostate cancer the most common malignancy among men in the United States. Center for Nuclear Receptors & Cell Signaling Assistant Professor Daniel Frigo and his research team recently published a study investigating the processes through which androgen receptors affect prostate cancer progression.
› Verified 2 days ago
Kathleen Anne Stumpf, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6500 Arapahoe Rd, Boulder, CO 80303 Phone: 303-447-1010 | |
Dhori Meyer Knud-hansen, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 1100 Balsam Ave, Boulder, CO 80304 Phone: 303-440-2100 | |
Amalia Beard, MOT, OTR Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 5412 Idylwild Trl, Boulder, CO 80301 Phone: 303-579-6149 | |
Celia Galvin, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 6214 Willow Ln, Boulder, CO 80301 Phone: 314-882-4569 | |
Courtney Whalen, OTR/L Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 4740 Pearl Pkwy, Boulder, CO 80301 Phone: 303-449-2730 | |
Jakki Ruzich, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 3850 Paseo Del Prado St Apt 36, Boulder, CO 80301 Phone: 702-612-7533 | |
David Mangine, Occupational Therapist Medicare: Not Enrolled in Medicare Practice Location: 7869 Brockway Dr, Boulder, CO 80303 Phone: 303-888-2819 |